Stevens-Johnson syndrome / toxic epidermal necrolysis: an Asia-Pacific perspective

Bernard Yu-Hor Thong

Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe cutaneous adverse reactions (SCAR) to drugs which are associated with significant morbidity and mortality. High risk drugs in Asia are similar to those reported worldwide. Human leukocyte antigen (HLA)-related risk alleles for carbamazepine and allopurinol SCAR are unique to Asians. Although prognostic scoring systems like the SCORTEN have been used for more than a decade, pitfalls and caveats need to be recognized, in particular in patients with multiple medical co-morbidities and systemic features in SJS/TEN. In centres without a tertiary Burns Centre, SJS/TEN patients can still be managed successfully in general and dermatology wards with well-executed supportive/nursing care. Controversy remains regarding the effectiveness of immunomodulation in reducing SJS/TEN morbidity, mortality and hastening re-epithelialization. Despite paucity of robust evidence, intravenous immunoglobulins and ciclosporin remain the most commonly used modalities worldwide. Acute and long-term ocular effects are an important source of morbidity for which emerging ophthalmic therapies appear promising. Quality of life issues have now become an important outcome in patients with SJS/TEN as they often impact survivors’ future attitudes towards pharmacotherapy. Even though pharmacogenetic testing for high-risk drugs appears to be the panacea for preventing carbamazepine- and allopurinol-induced SJS/TEN in ethnic Asians, many issues remain before health regulators in our region can conclusively determine whether testing should be made mandatory or highly recommended as standard of care.

Key words: HLA antigens; Immunomodulatory therapy; Pharmacogenetics; Quality of life

Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe cutaneous adverse reactions (SCAR) to drugs which are associated with significant morbidity and mortality [1]. Initially thought to be discrete entities with different pathogenesis, we now know that SJS/TEN may be a continuum depending on the extent of body surface area (BSA) affected by epidermal detachment (>30% in established TEN versus 10-30% in SJS/TEN overlap), and the extent of mucosal involvement (at least 2 mucosal surfaces comprising ocular, oral and genital) [2, 3]. SJS/TEN may also have organ-specific or systemic involvement found in drug reaction with eosinophilia and systemic symptoms (DRESS) or drug induced hypersensitivity syndromes (DiHS) [4-6].

Correspondence: Bernard Yu-Hor Thong
Department of Rheumatology, Allergy and Immunology, Tan Tock Seng Hospital, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore
Tel: +65-6357-7822
Fax: +65-6357-2686
E-mail: bernard_thong@ttsh.com.sg

Received: September 16, 2013
Accepted: September 22, 2013

This is an Open Access article distributed under the terms of the Creative Commons Attribution. Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
These include fever, leukocytosis, eosinophilia, hepatitis and acute interstitial nephritis where viral reactivation of herpes viruses have been demonstrated to be one of the known triggers [6].

**Risk factors: drug- and human leukocyte antigen (HLA)-related**

Drugs with increased risk for SJS/TEN have been classified based on data from the RegisSCAR/ EuroSCAR registry into [7, 8]:

- High risk drugs e.g. allopurinol, carbamazepine, cotrimoxazole and other anti-infective sulfonamides, sulfasalazine, lamotrigine, nevirapine, non-steroidal anti-inflammatory drugs (NSAID - oxicam type; e.g. meloxicam), phenobarbital, phenytoin;
- Moderate risk drugs e.g. cephalosporins, macrolides, quinolones, tetracyclines, NSAIDs (acetic acid type; e.g. diclofenac);
- Low risk e.g. beta-blockers, angiotensin-converting enzyme inhibitors, calcium channel blockers, thiazide diuretics (with sulfonamide structure), sulfonylurea anti-diabetics (with sulfonamide structure), insulin, NSAIDs (propionic acid type; e.g. ibuprofen)

The pattern of causative drugs for SJS/TEN is similar in many countries within the Asia-Pacific region [9-12].

Genetic risk factors for SJS/TEN have been found to be generally ethnicity- and drug-specific [13]. Much of the work on genetic risk factors for SJS/TEN have originated from Asian ancestry. HLA-B*1502 was first found by the Taiwanese to be associated with carbamazepine (CBZ) induced SJS in Han Chinese [14] in 2004, then subsequently among the Thais [15], Indians [16] and Malays [17] as well. However, HLA-B*1511 was found to be associated with CBZ SJS/TEN and A*3101 with CBZ SJS/DiHS in Japanese [18, 19] and Koreans [20] rather than HLA-B*1502.

In 2005, HLA-B*5801 was found by the same Taiwanese group to be associated with allopurinol SJS/TEN in Han Chinese [21], followed subsequently by a similar association in Thais [22], Japanese [23] and Koreans [24].

Human immunodeficiency virus (HIV) infection, which is endemic in certain countries in the Asia-Pacific [25], is associated with a higher incidence of drug hypersensitivity [26], with an increased risk for SJS/TEN associated mainly with nevirapine and cotrimoxazole [27, 28]. Co-infection with HIV and tuberculosis, more than 40% skin involvement, and severe sepsis have been found to be poor prognostic factors [29].

**Prognostic scoring systems: pitfalls and caveats**

The Score of TEN (SCORTEN) is a severity-of-illness score used to predict the risk of death from TEN upon admission [30]. It comprises the following 7 independent risk factors (variables): age ≥40 years, tachycardia ≥120 beats per minute, presence of cancer/haematologic malignancy, BSA involved on day 1, elevated serum urea (>10 mmol/L), acidemia (serum bicarbonate <20 mmol/L) and hyperglycemia (serum glucose >14 mmol/L), scored within the first 24 h of admission. Recent criticisms on the use of SCORTEN include the underestimation of the effects of pre-existing common or complex co-morbidities (e.g. diabetes mellitus), severity of these co-morbidities [31], and respiratory involvement [32] on outcomes of TEN. SCORTEN also does not take into account patients with SJS/TEN who may also have other features of DRESS/DiHS. A recent study showed that 5 independent prognostic risk factors for death in DRESS were: heart rate >90 beats per minute, white blood cells >12,000/mm$^3$, respiratory rate >20/min (at early disease stage), coagulopathy and gastrointestinal bleeding (at maximal disease stage). DRESS patients with persistent systemic inflammatory response syndrome during hospitalization were also associated with higher mortality risk [33]. Thus SCORTEN may not be the ideal prognostic index for mortality in patients with other non-haematological/non-oncological chronic diseases, and organ/systems involvement from DiHS/DRESS.

**Supportive management: is transfer to a Burns Centre essential?**

Immediate cessation of the suspected causative drug is key to the management of SJS/TEN. However, immunological mechanisms in SJS/TEN may continue to progress despite cessation of the correct causative drug. Supportive care includes maintenance of thermoregulation (30-32°C), fluid/volume replacement with electrolyte and albumin solution, changing of dressing, wound debridement, enteral nutrition if needed, and prevention of infections [34]. Although admission to a specialized Burns Centre is ideal [35, 36], where there are limited resources, when patients present acutely to a rural or district hospital, or may be unfit for transfer, they may need to be managed in the general/dermatology ward or a high dependency area with strict infection control and where nurses are/can be trained in the dressing of denuded skin. From SJS/TEN cohorts from the Asia-Pacific, there have only been 2 cohorts exclusively managed within a Burns Centre in Singapore [37] and Hong Kong [38]. It is likely that some
cohort of SJS/TEN patients from other centres have also included patients managed in a tertiary burns unit with an attending dermatologist, internist or allergist. From the literature, it is difficult to ascertain whether the outcomes were better because of the higher level of specialist and nursing care available, or worse because these were likely to have been sicker patients. There have been no published cohorts to date of paediatric patients in the Asia-Pacific region with SJS/TEN managed exclusively in a Burns Centre.

Immunomodulation: where are we in 2013?

Despite on-going controversy as to whether high dose intravenous immunoglobulins (IVIg) at a dose of 2 g/kg reduces mortality in TEN [39], up to 50% of practitioners worldwide continue to use this as the most common form of immunomodulatory therapy for TEN [40]. The evidence for IVIg has been confounded by data coming predominantly from retrospective case series, with variable inclusion criteria, high and low-risk patients included, and patients with not just TEN, but also SJS/TEN overlap [41-43]. The most common cause of mortality was renal failure in most of these studies. A recent systematic review and meta-analysis of the literature did not show any clinical benefit of IVIg in both children and adults [44]. Recent case reports/series on the use of intravenous methylprednisolone with IVIg [45], and corticosteroids with infliximab and IVIg [46] have been reported to be effective in arresting progression of TEN and reducing mortality.

There has been renewed interest in the use of ciclosporin, the second most commonly used treatment for TEN in a worldwide survey [40]. An open, phase II trial to determine the safety and possible benefit of ciclosporin on 29 patients showed that ciclosporin 3 mg/kg/d for 10 days and tapered over another 7 days, when given early was not associated with any mortality in SJS, SJS/TEN and TEN, and stabilized epidermal detachment [47]. In a study from India, where ciclosporin was administered at a dose of 3 mg/kg body for 7 days and then tapered over another 7 days, there was no mortality [48]. The limiting factors precluding the use of ciclosporin and dose optimization would be the development of acute kidney injury as a result of TEN, hypovolemia or sepsis.

The use of systemic corticosteroids was evaluated in a case-control study based on data collected from the EuroSCAR and RegiSCAR studies [49]. The prior use of corticosteroids prolonged the period of disease progression by 2.2 days [95% confidence interval (CI) 1.1-3.2] without influencing the disease severity or mortality, and delayed time to onset of SJS/TEN with exposure to high-risk drugs by 7.1 days (95% CI -0.2 to 14.5). Apart from case series and case reports, of which one showed histological improvement of epidermal necrolysis on serial skin biopsies [50], there remain no controlled studies on the use of systemic corticosteroids in TEN.

The use of cyclophosphamide [51], anti-tumour necrosis factor (TNF) inhibitors [52-54], and plasma exchange remain [55] unsupported by controlled studies. The only randomized controlled trial of immunomodulatory treatment to date has been the use of thalidomide for its anti-TNF effect where there was an increase in mortality demonstrated in the thalidomide group, leading to early cessation of the study [56].

Controlled studies on treatment of SJS/TEN in children are also lacking. In a systematic review, where meta-analysis was found not to be feasible, 4 main treatment modalities were assessed among 128 cases. These were: IVIg, systemic corticosteroids (prednisolone, methylprednisolone, dexamethasone), dressings with or without surgical debridement, and supportive treatment alone. Other miscellaneous treatments analysed included plasma exchange, intravenous pentoxifylline and use of ciclosporin. Steroids and IVIg appeared to improve the outcome of SJS and TEN but the results from different reports were highly variable [57].

Acute and chronic ocular effects

Early involvement of the eye in SJS/TEN may be mild (eyelid edema, mild conjunctival injection, chemosis), moderate (membranous conjunctivitis, corneal epithelial defects, corneal ulceration, corneal infiltrates) or severe (symblepharon, non-healing corneal epithelial defects, visual loss, conjunctival fornix foreshortening). Late effects of SJS/TEN include sicca syndrome due to lacrimal duct damage and trichaitic lashes [58, 59]. The extent and severity of acute ocular involve need not correlate with the degree of skin severity [60, 61]. Topical steroids, topical antibiotics and lubricants are often used in the acute phase [60-62]. Topical ciclosporin may be useful for inflammation and chronic dry eyes [63]. There is little evidence to date on the effect of IVIg on ocular outcomes [64]. Case series have shown variable benefit of non-steroid immunosuppressive drugs including azathioprine, mycophenolate, ciclosporin, infliximab, and adalimumab for recurrent ocular inflammation/ scleritis [65]. Surgical ophthalmic intervention in the form of amniotic membrane transplantation applied to the eyes and eyelids in the acute phase appear to be useful in preventing scarring and visual problems that characterize the chronic phase of the disease. The severe, chronic ocular
problems can at least be partially alleviated with autologous serum drops, mucous membrane grafting to replace scarred tarsal conjunctiva, specialized contact lenses, conjunctival replacement surgery, limbal stem cell transplantation and keratoprosthesis [66].

Health related quality of life in survivors

Health related quality of life (HRQL) in allergic and immunologic diseases [67] has been increasingly studied in asthma, rhinoconjunctivitis [68], food allergy [69], and recently drug hypersensitivity [70]. Validated instruments have been generated both for the patient and care givers in certain conditions like food allergy. However, most of these instruments are used as research tools, and are in English. They will thus require translation, back translation and local validation should they be used for clinical care in the Asia-Pacific region. Items in some of the disease specific instruments may not be directly relevant to certain Asian societies/ ethnicities e.g. types of food in a food allergy related HRQL instrument. Despite SJS/TEN being rare, survivors nonetheless experience significant psychological stress and fear following this potentially life-threatening reaction, particularly in their attitudes towards future use of drugs [71]. For instance, a patient with recurrent infections who had experienced SJS/TEN to a betalactam antibiotic may become overly cautious with the next antibiotic course. The choice of an alternative anti-epileptic drug in a patient who has experienced carbamazepine induced SJS/TEN may also create some anxiety. It is thus crucial that health care professionals involved in the care of patients with a history of SJS/TEN be aware of potential long-term psychological sequelae and effects on the doctor-patient relationships [72]. Patients with chronic end-organ impairment or damage e.g. chronic dry eyes and visual impairment would have other physical concerns that need to be addressed. With multiple internet websites and social networking platforms, health professionals need to be even more aware of the extent of accurate information or misinformation, and perceptions that patients and their care-givers may have as a result of their experiences during an episode of SJS/TEN.

Prevention: controversies with HLA pharmacogenetic testing in Asia

In December 2007, the United States Food and Drug Administration recommended HLA-B*1502 testing prior to the use of CBZ in Asians. HLA testing has since been made mandatory in Hong Kong and Taiwan; and highly recommended as standard of care in Singapore since April 2013. In a Taiwanese study using HLA-B*1502 screening to prospectively identify subjects at genetic risk for CBZ SJS/TEN, among 4,877 candidate subjects who had not taken CBZ previously, those who tested HLA-B*1502 positive (7.7%) were advised not to take CBZ; and those who tested HLA-B*1502 negative (92.3%) were advised to take CBZ. Using an estimated historical incidence of SJS-TEN as a control (0.23%), it was found that SJS-TEN did not develop in any of the HLA-B*1502-negative subjects receiving CBZ (p < 0.001) [73]. The use of a historical cohort as the control group was a weakness in this study. This is in contrast to the PREDICT-I study on the use of HLA-B*5701 to predict abacavir hypersensitivity, where the control group was an active treatment group with standard-of-care approach to abacavir use without prospective HLA-B*5701 screening [74].

Unanswered questions remain on HLA-B*1502 screening for CBZ SJS/TEN in Asia. Firstly whether other aromatic anticonvulsants should also be avoided (phenytoin (PHT), oxcarbazepine (OXC), lamotrigine (LTG)) in those who test HLA-B*1502 positive remains uncertain. A case-control association study [75] of 26 PHT, 6 LTG and 3 OXC-induced SJS/TEN patients, were compared with 113 PHT-tolerant, 67 LTG-tolerant subjects, and 93 normal subjects from the general population all of Asian ancestry. HLA-B*1502 was present in 8/26 (30.8%) PHT-SJS/TEN (odds ratio (OR) 5.1; 95% CI 1.8-15.1; p = 0.0041), 2/6 (33%) LTG-SJS (OR 5.1; 95% CI 0.8-33.8; p = 0.1266) and 3/3 (100%) OXC-SJS (OR 80.7; 95% CI 3.8-1714.4; p = 8.4 x 10^-4) patients. In addition, HLA-B*1301, Cw*0801 and DRB1*1602 also showed an association with PHT-SJS/TEN (p = 0.0128-0.0281; OR 3.0-4.3).

Secondly, the definition of Asian and south-east Asian ancestry can be difficult to define especially with increasing inter-ethnic marriages within the region. Of note, HLA-B*1502 associations with CBZ SJS/TEN do not seem to hold true in certain parts of East Asia (Korea and Japan).

Thirdly, the question of cost-effectiveness may not be a straightforward one to answer as it depends on funding mechanisms for pharmacogenetic testing, and costs of alternative anti-epileptic drugs. In Hong Kong and Taiwan, the HLA-B*1502 tests are free to patients. In Singapore, the tests are subsidized only up to 25% for government-subsidized (public) patients; private full-paying patients pay for the test in full. A cost-effectiveness study using a decision tree model [76] suggested that genotyping for HLA-B*1502 and providing alternate anti-epileptic drugs to those who test positive is cost-effective for Singaporean Chinese and Malays, but not for Singaporean Indians. However, the limitations of the study [77] included both PHT and CBZ being
used interchangeably in the model rather than CBZ alone, and the costs of long-term sequelae, especially ocular sequelae not being considered in the model. Depending on the health care structure in countries where private general practitioners are not funded, this may drive private primary care providers to refer all their patients to public hospitals to gain easy access to subsidized HLA testing. The costs of alternative, newer anti-epileptic drugs which are generally more expensive (e.g. topiramate, levetiracetam) in the setting of CBZ SJS/TEN, needs to be considered [78].

Lastly, cases with CBZ-induced SJS/TEN negative for HLA-B*1502 have been reported from East and Southeast Asia [79]. Negative correlations between CBZ-induced SJS/TEN and B*0702 or B*4001 have also been reported, suggesting a possible protective role. Thus, physicians should also be vigilant about SJS/TEN in those negative for HLA-B*1502. Other factors for the development of CBZ-induced SJS/TEN in HLA-B*1502-negative patients and protective factors in CBZ-tolerant patients are likely to exist.

It is likely that the Asia-Pacific will next be faced with the problem of testing for HLA-B*5801 prior to prescription of allopurinol, and whether this should be recommended or made mandatory [80]. Apart from similar issues with CBZ SJS/TEN, potential issues in the Asia-Pacific with HLA-B*5801 testing for allopurinol include limited treatment options in patients with tophaceous gout and chronic kidney disease (where uricosuric agents are ineffective), and limited access to and costs of feboxostat and recombinant urate oxidase [81] in the region. On the other hand, patients with chronic kidney disease and positive for HLA-B*5801 have been shown to be at higher risk of allopurinol-induced SCAR. Hence making testing even more beneficial in this group of patients [82].

**CONCLUSION**

Although the Asia-Pacific region faces many similar issues as western populations in the management of SJS/TEN, differences in ethnic composition and health care financing structures will impact the extent to which pharmacogenetic testing can or should be implemented in different geographic regions. Limited access and poverty in rural regions means that patients with acute SJS/TEN will need to be stabilized quickly and referred to urban tertiary centres with access to expensive immunomodulatory drugs and specialist/intensive care as soon as possible. Awareness of prescribers of high-risk drugs, close monitoring for drug eruptions/systemic symptoms, and the use of simple tests like the full (complete) blood count, tests of renal and liver function, with immediate cessation of the culprit drug may be the most "cost-effective" method where specialized tests and specialist care are not readily available. Nonetheless, all health professionals and patients should be educated on potential danger symptoms and signs of SJS/TEN to look out for when taking high-risk drugs. This will go a long way in preventing long-term psychological sequelae in survivors, and disruption of the doctor-patient relationship in clinical decision making.

**REFERENCES**

1. Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 1993;129:92-6.

2. Mockenhaupt M. The current understanding of Stevens-Johnson syndrome and toxic epidermal necrolysis. Expert Rev Clin Immunol 2011;7:803-15.

3. French LE. Toxic epidermal necrolysis and Stevens Johnson syndrome: our current understanding. Allergol Int 2006;55:9-16.

4. Bocquet H, Bagot M, Roujeau JC. Drug-induced pseudolymphoma and drug hypersensitivity syndrome (Drug Rash with Eosinophilia and Systemic Symptoms: DRESS). Semin Cutan Med Surg 1996;15:250-7.

5. Sontheimer RD, Hoepff KR. DIDMOHS: a proposed consensus nomenclature for the drug-induced delayed multiorgan hypersensitivity syndrome. Arch Dermatol 1998;134:874–6.

6. Shiohara T, Inaoka M, Kano Y. Drug-induced hypersensitivity syndrome (DIHS): a reaction induced by a complex interplay among herpesviruses and antiviral and antidrug immune responses. Allergol Int 2006;55:1-8.

7. Mockenhaupt M, Viboud C, Dunant A, Naldi L, Halevy S, Bouwes Bavinck JN, Sidoroff A, Schneck J, Roujeau JC, Flahault A. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol 2008;128:35-44.

8. Sassolas B, Haddad C, Mockenhaupt M, Dunant A, Liss Y, Bork K, Haustein UF, Vieluf D, Roujeau JC, Le Louet H. ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson Syndrome and toxic epidermal necrolysis: comparison with case-control analysis. Clin Pharmacol Ther 2010;88:60-8.

9. Singalavanija S, Limponsanurak W. Stevens-Johnson syndrome in...
Thai children: a 29-year study. J Med Assoc Thai 2011;94 Suppl 3:S85-90.

10. Tan SK, Tay YK. Profile and pattern of Stevens-Johnson syndrome and toxic epidermal necrolysis in a general hospital in Singapore: treatment outcomes. Acta Derm Venereol 2012;92:62-6.

11. Choon SE, Lai NM. An epidemiological and clinical analysis of cutaneous adverse drug reactions seen in a tertiary hospital in Johor, Malaysia. Indian J Dermatol Venereol Leprol 2012;78:734-9.

12. Kim HI, Kim SW, Park GY, Kwon EG, Kim HH, Jeong JY, Chang HH, Lee JM, Kim NS. Causes and treatment outcomes of Stevens-Johnson syndrome and toxic epidermal necrolysis in 82 adult patients. Korean J Intern Med 2012;27:203-10.

13. Lonjou C, Thomas L, Borot N, Ledger N, de Toma C, LeLouet H, Graf E, Schumacher M, Hovnanian A, Mockenhaupt M, Roujeau JC. A marker for Stevens-Johnson syndrome ...: ethnicity matters. Pharmacogenomics 2006;6:265-8.

14. Chung WH, Hung SI, Hong HS, Hsih MS, Yang LC, Ho HC, Wu JY, Chen YT. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004;428:486.

15. Locharernkul C, Lopumlert J, Limotai C, Korkij W, Desudchit T, Tongkobpetch S, Kangwanshiratada O, Hirankarn N, Suphapeetiporn K, Shotelersuk V. Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population. Epilepsia 2008;49:2087-91.

16. Mehta TY, Prajapati LM, Mittal B, Joshi CG, Sheth JJ, Patel DB, Dave DM, Goyal RK. Association of HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome among Indians. Indian J Dermatol Venereol Leprol 2009;75:579-82.

17. Chang CC, Too CL, Murad S, Hussein SH. Association of HLA-B*1502 allele with carbamazepine-induced toxic epidermal necrolysis and Stevens-Johnson syndrome in the multi-ethnic Malaysian population. Int J Dermatol 2011;50:221-4.

18. Kaniwa N, Saito Y, Aihara M, Matsunaga K, Tohkin M, Kurose K, Sawada J, Furuya H, Takahashi Y, Muramatsu M, Kinoshita S, Abe M, Ikeda H, Kashiwagi M, Song Y, Ueta M, Sotozono C, Ikezawa Z, Hasegawa R. HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrosis. Pharmacogenomics 2008;9:1617-22.

19. Kang HR, Jee YK, Kim YS, Lee CH, Jung JW, Kim SH, Park HW, Chang YS, Jang IJ, Cho SH, Min KU, Kim SH, Lee KW. Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans. Pharmacogenet Genomics 2011;21:303-7.

20. Chan R. Sexually transmitted infections in Asia and the Pacific--an epidemiological snapshot. Sex Transm Infect 2011;87 Suppl 2:ii14-5.

21. Phillips E, Mallal S. Drug hypersensitivity in HIV. Curr Opin Allergy Clin Immunol 2007;7:324-30.

22. Choonhakarn C, Pisuttimarn P, Sangviroon A, Tassaneeyakul W. Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrosis in a Thai population. J Intern Med 2012;27:203-10.

23. Choon SE, Lai NM. An epidemiological and clinical analysis of cutaneous adverse drug reactions seen in a tertiary hospital in Johor, Malaysia. Indian J Dermatol Venereol Leprol 2012;78:734-9.

24. Kaniwa N, Saito Y, Aihara M, Matsunaga K, Tohkin M, Kurose K, Sawada J, Furuya H, Takahashi Y, Muramatsu M, Kinoshita S, Abe M, Ikeda H, Kashiwagi M, Song Y, Ueta M, Sotozono C, Ikezawa Z, Hasegawa R. HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrosis. Pharmacogenomics 2008;9:1617-22.

25. Kang HR, Jee YK, Kim YS, Lee CH, Jung JW, Kim SH, Park HW, Chang YS, Jang IJ, Cho SH, Min KU, Kim SH, Lee KW. Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans. Pharmacogenet Genomics 2011;21:303-7.

26. Chan R. Sexually transmitted infections in Asia and the Pacific--an epidemiological snapshot. Sex Transm Infect 2011;87 Suppl 2:ii14-5.

27. Phillips E, Mallal S. Drug hypersensitivity in HIV. Curr Opin Allergy Clin Immunol 2007;7:324-30.

28. Choonhakarn C, Pisuttimarn P, Sangviroon A, Tassaneeyakul W. Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrosis in a Thai population. J Intern Med 2012;27:203-10.

29. Choon SE, Lai NM. An epidemiological and clinical analysis of cutaneous adverse drug reactions seen in a tertiary hospital in Johor, Malaysia. Indian J Dermatol Venereol Leprol 2012;78:734-9.

30. Kaniwa N, Saito Y, Aihara M, Matsunaga K, Tohkin M, Kurose K, Sawada J, Furuya H, Takahashi Y, Muramatsu M, Kinoshita S, Abe M, Ikeda H, Kashiwagi M, Song Y, Ueta M, Sotozono C, Ikezawa Z, Hasegawa R. HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrosis. Pharmacogenomics 2008;9:1617-22.

31. Kang HR, Jee YK, Kim YS, Lee CH, Jung JW, Kim SH, Park HW, Chang YS, Jang IJ, Cho SH, Min KU, Kim SH, Lee KW. Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans. Pharmacogenet Genomics 2011;21:303-7.

32. Chan R. Sexually transmitted infections in Asia and the Pacific--an epidemiological snapshot. Sex Transm Infect 2011;87 Suppl 2:ii14-5.

33. Phillips E, Mallal S. Drug hypersensitivity in HIV. Curr Opin Allergy Clin Immunol 2007;7:324-30.

34. Choonhakarn C, Pisuttimarn P, Sangviroon A, Tassaneeyakul W. Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrosis in a Thai population. J Intern Med 2012;27:203-10.
Stevens-Johnson syndrome and toxic epidermal necrolysis

Are Multimorbidity Underestimated in Scoring Systems of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Like in SCORTEN? Eplasty 2012;12:e35.

32. Hague JS, Goulding JM, Long TM, Gee BC. Respiratory involvement in toxic epidermal necrolysis portends a poor prognosis that may not be reflected in SCORTEN. Br J Dermatol 2007;157:1294-6.

33. Wei CH, Chung-Yee Hui R, Chang CJ, Ho HC, Yang CH, Lin YI, Chung WH. Identifying prognostic factors for drug rash with eosinophilia and systemic symptoms (DRESS). Eur J Dermatol 2011;21:930-7.

34. Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis: Part II. Prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment. J Am Acad Dermatol 2013;69:187.e1-187.e16.

35. Weinand C, Xu W, Perbix W, Lefering R, Maegle M, Rathert M, Spilker G. 27 years of a single burn centre experience with Stevens-Johnson syndrome and toxic epidermal necrolysis: Analysis of mortality risk for causative agents. Burns 2013. pii: S0305-4179(13)00085-5.

36. Cartotto R, Mayich M, Nickerson D, Gomez M. SCORTEN accurately predicts mortality among toxic epidermal necrolysis patients treated in a burn center. J Burn Care Res 2008;29:141-6.

37. Kho AK, Foo CL. Toxic epidermal necrolysis in a burns centre: a 6-year review. Burns 1996;22:275-8.

38. Ying S, Ho W, Chan HH. Toxic epidermal necrolysis: 10 years experience of a burns centre in Hong Kong. Burns 2001;27:372-5.

39. Lee HY, Lim YL, Thirumoorthy T, Pang SM. The role of intravenous immunoglobulins in toxic epidermal necrolysis: a retrospective analysis of 64 patients managed in a specialized centre. Br J Dermatol 2013. doi: 10.1111/bjd.12607.

40. Thong BY, Mirakian R, Castells M, Pichler W, Romano A, Bonadonna P, Diana D, Kowalski M, Yanez A, Lleonart R, Sanchez-Borges M, Demoly P. A world allergy organization international survey on diagnostic procedures and therapies in drug allergy/hypersensitivity. World Allergy Organ J 2011;4:257-70.

41. Viard I, Wehrli P, Bullani R, Schneider P, Holler N, Salomon D, Hunziker T, Saurat JH, Tschopp J, French LE. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998;280:492-3.

42. Prins C, Kerdel FA, Padilla RS, Hunziker T, Chimenti S, Viard I, Mauri DN, Flynn K, Trent J, Margolis DJ, Saurat JH, French LE. Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol 2003;139:26-32.

43. Bachot N, Revuz J, Roujeau JC. Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression. Arch Dermatol 2003;139:33-6.

44. Huang YC, Li YC, Chen TJ. The efficacy of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis: a systematic review and meta-analysis. Br J Dermatol 2012;167:424-32.

45. Zhu QY, Ma L, Luo XQ, Huang HY. Toxic epidermal necrolysis: performance of SCORTEN and the score-based comparison of the efficacy of corticosteroid therapy and intravenous immunoglobulin combined therapy in China. J Burn Care Res 2012;33:e295-308.

46. Gaitanis G, Spyridonos P, Patmanidis K, Koulouras V, Nakos G, Tzaphlidou M, Bassukas ID. Treatment of toxic epidermal necrolysis with the combination of infliximab and high-dose intravenous immunoglobulin. Dermatology 2012;224:134-9.

47. Valeyrice-Allanore L, Wolkenstein P, Brochard L, Ortonne N, Maitre B, Revuz J, Bagot M, Roujeau JC. Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol 2010;163:847-53.

48. Singh GK, Chatterjee M, Verma R. Cyclosporine in Stevens Johnson syndrome and toxic epidermal necrolysis and retrospective comparison with systemic corticosteroid. Indian J Dermatol Venereal Leprol 2013;79:686-92.

49. Lee HY, Dunant A, Sekula P, Mockenhaupt M, Wolkenstein P, Valeyrice-Allanore L, Naldi L, Halevy S, Roujeau JC. The role of prior corticosteroid use on the clinical course of Stevens-Johnson syndrome and toxic epidermal necrolysis: a case-control analysis of patients selected from the multinational EuroSCAR and RegiSCAR studies. Br J Dermatol 2012;167:555-62.

50. O’Donoghue JM, Céspedes YR, Rockley PF, Ngira TP. Skin biopsies to assess response to systemic corticosteroid therapy in early-stage TEN: case report and review of the literature. Cuts 2009;84:138-40, 161-2.

51. Heng MC, Allen SG. Efficacy of cyclophosphamide in toxic epidermal necrolysis. Clinical and pathophysiologic aspects. J Am Acad Dermatol 1991;25:778-86.

52. Gubinelli E, Canzona F, Tonanzi T, Raskovic D, Didona B. Toxic epidermal necrolysis successfully treated with etanercept. J Dermatol 2009;36:150-3.

53. Wojtikiewicz A, Wysocki M, Fortuna J, Chrupek M, Matczuk M, Koltan A. Beneficial and rapid effect of infliximab on the course of toxic epidermal necrolysis. Acta Derm Venerolog 2008;88:420-1.

54. Hunger RE, Hunziker T, Buettiker U, Braathen LR, Yawalkar N. Rapid resolution of toxic epidermal necrolysis with anti-TNF-alpha treatment. J Allergy Clin Immunol 2005;116:923-4.

55. Bamichas G, Natse T, Christidou F, Stangou M, Karagianni A,
Koukourikos S, Chaidemenos G, Chrysomallis F, Sombolos K. Plasma exchange in patients with toxic epidermal necrolysis. Ther Apher 2002;6:225-8.

56. Wolkenstein P, Latarjet J, Roujeau JC, Duguet C, Boudeau S, Vaillant L, Maignan M, Schuhmacher MH, Milbied B, Pilorget A, Bocquet H, Brun-Buisson C, Revuz J. Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet 1998;352:1586-9.

57. Del Pozzo-Magana BR, Lazo-Langner A, Carleton B, Castro-Pastrana LJ, Rieder MJ. A systematic review of treatment of drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in children. J Popul Ther Clin Pharmacol 2011;18:e121-33.

58. Chang YS, Huang FC, Tseng SH, Hsu CK, Ho CL, Sheu HM. Erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis: acute ocular manifestations, causes, and management. Cornea 2007;26:123-9.

59. Yip LW, Thong BY, Lim J, Tan AW, Wong HB, Handa S, Heng WJ. Ocular manifestations and complications of Stevens-Johnson syndrome and toxic epidermal necrolysis: an Asian series. Allergy 2007;62:527-31.

60. López-García JS, Rivas Lara L, García-Lozano CI, Conesa E, de Juan IE, Murube del Castillo J. Ocular features and histopathologic changes during follow-up of toxic epidermal necrolysis. Ophthalmology 2011;118:265-71.

61. Gueudry J, Roujeau JC, Binaghi M, Soubrene G, Muraine M. Risk factors for the development of ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis. Arch Dermatol 2009;145:157-62.

62. Sotozono C, Ueta M, Koizumi N, Inatomi T, Shirakata Y, Ikezawa Z, Hashimoto K, Kinoshita S. Diagnosis and treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis with ocular complications. Ophthalmology 2009;116:685-90.

63. Prabhasawat P, Tesavibul N, Karnchanachetanee C, Kasemson S. Efficacy of cyclosporine 0.05% eye drops in Stevens Johnson syndrome with chronic dry eye. J Ocul Pharmacol Ther 2013;29:372-7.

64. Yip LW, Thong BY, Tan AW, Khin LW, Chng HH, Heng WJ. High-dose intravenous immunoglobulin in the treatment of toxic epidermal necrolysis: a study of ocular benefits. Eye (Lond) 2005;19:846-53.

65. De Rojas MV, Dart JK, Saw VP. The natural history of Stevens Johnson syndrome: patterns of chronic ocular disease and the role of systemic immunosuppressive therapy. Br J Ophthalmol 2007;91:1048-53.

66. Cirlsky JB, Sippel KC, Gregory DG. Current ophthalmologic treatment strategies for acute and chronic Stevens-Johnson syndrome and toxic epidermal necrolysis. Curr Opin Ophthalmol 2013;24:321-8.

67. Baiardini I, Braido F, Brandi S, Canonica GW. Allergic diseases and their impact on quality of life. Ann Allergy Asthma Immunol 2006;97:419-28.

68. Petersen KD, Kronborg C, Gyrd-Hansen D, Dahl R, Larsen JN, Lowenstein H. Quality of life in rhinoconjunctivitis assessed with generic and disease-specific questionnaires. Allergy 2008;63:284-91.

69. Salvilla SA, Paneses SS, Patel S, Rader T, Muraro A, Roberts G, de-Blok BF, Dubois A, Sheikh A. Disease-specific health-related quality of life (HRQL) instruments for food allergy: protocol for a systematic review. Clin Transl Allergy 2013;3:15.

70. Baiardini I, Braido F, Fassio O, Calia R, Giorgio WC, Romano A. Development and validation of the Drug Hypersensitivity Quality of Life Questionnaire. Allergen Asthma Immunol 2011;106:330-5.

71. Butt TF, Cox AR, Lewis H, Ferner RE. Patient experiences of serious adverse drug reactions and their attitudes to medicines: a qualitative study of survivors of Stevens-Johnson syndrome and toxic epidermal necrolysis in the UK. Drug Saf 2011;34:29-38.

72. Roujeau JC. Stevens-Johnson Syndrome and toxic epidermal necrolysis: improving the support to victims. Drug Saf 2013;36:145-6.

73. Chen P, Lin JJ, Lu CS, Ong CT, Hsieh PF, Yang CC, Tai CT, Wu SL, Lu CH, Hsu YC, Yu HY, Ro LS, Lu CT, Chu CC, Tsai JJ, Su YH, Lan SH, Sung SF, Lin SY, Chuang HP, Huang LC, Chen YJ, Tsai PI, Liao HT, Lin YH, Chen CH, Chung WH, Hung SI, Wu JY, Chang CF, Chen L, Yen YT, Shen CY. Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. N Engl J Med 2011;364:1126-33.

74. Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J, Jägel-Guedes E, Ruginza S, Kozyrev O, Cid JF, Hay P, Nolan D, Hughes S, Hughes A, Ryan S, Fitch N, Thorborn D, Benbow A. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008;358:568-79.

75. Hung SI, Chung WH, Liu ZS, Chen CH, Hsih MS, Hui RC, Chu CY, Chen YT. Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese. Pharmacogenomics 2010;11:349-56.

76. Dong D, Sung C, Finkelstein EA. Cost-effectiveness of HLA-B*1502 genotyping in adult patients with newly diagnosed epilepsy in Singapore. Neurology 2013;80:1621.

77. Hung SI, Chung WH. Cost-effectiveness of HLA-B*1502 genotyping in adult patients with newly diagnosed epilepsy in Singapore. Neurology 2013;80:1621.

78. Wilby J, Kainth A, Hawkins N, Epstein D, McIntosh H, McDaid C, Mason A, Golder S, O’Meara S, Sculpter M, Drummond M, Forbes C. Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation. Health Technol Assess 2005;9:1-157, iii-iv.
79. Shi YW, Min FL, Qin B, Zou X, Liu XR, Gao MM, Wang Q, Zhou JQ, Liao WP. Association between HLA and Stevens-Johnson syndrome induced by carbamazepine in Southern Han Chinese: genetic markers besides B*1502? Basic Clin Pharmacol Toxicol 2012;111:58-64.

80. Hershfield MS, Callaghan JT, Tassaneeyakul W, Mushiroda T, Thorn CF, Klein TE, Lee MT. Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing. Clin Pharmacol Ther 2013;93:153-8.

81. Calogiuri G, Nettis E, Di Leo E, Foti C, Ferrannini A, Butani L. Allopurinol hypersensitivity reactions: desensitization strategies and new therapeutic alternative molecules. Inflamm Allergy Drug Targets 2013;12:19-28.

82. Jung JW, Song WJ, Kim YS, Joo KW, Lee KW, Kim SH, Park HW, Chang YS, Cho SH, Min KU, Kang HR. HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency. Nephrol Dial Transplant 2011;26:3567-72.